Cartesian Therapeutics Announces New Employment Inducement Grants
08 nov. 2024 07h05 HE
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07 nov. 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
05 nov. 2024 09h00 HE
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
15 oct. 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces New Employment Inducement Grants
04 oct. 2024 07h05 HE
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
09 sept. 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces New Employment Inducement Grant
06 sept. 2024 07h05 HE
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
03 sept. 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. ...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
26 août 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 07h00 HE
|
Cartesian Therapeutics, Inc.
Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2...